Effect of Long-Term Allopurinol Therapy on Left Ventricular Mass Index in Patients with Ischemic Heart Disease; A Cross-Sectional Study

• Published in: Vascular health and risk management 2019-01, Vol.15, p.539-550
• Main Authors: Alem, Manal M, Aldosari, Sarah R, Alkahmous, Alhassna A, Obad, Adam S, Fagir, Nagy M, Al-Ghamdi, Bandar S
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; allopurinol; Allopurinol - adverse effects; Allopurinol - therapeutic use; Antioxidants - adverse effects; Antioxidants - therapeutic use; Biomarkers - blood; Blood Glucose - drug effects; Blood Glucose - metabolism; Cardiovascular disease; Case-Control Studies; Creatinine - blood; Cross-Sectional Studies; Drug dosages; Ejection fraction; Female; Glucose; Glycated Hemoglobin A - metabolism; glycemic control; hba1c; Health risk assessment; Hemoglobin; Humans; Hypertrophy, Left Ventricular - blood; Hypertrophy, Left Ventricular - diagnostic imaging; Hypertrophy, Left Ventricular - drug therapy; Hypertrophy, Left Ventricular - physiopathology; ihd; Insulin resistance; Ischemia; left ventricular geometry; lvmi; Male; Medical imaging; Middle Aged; Myocardial Ischemia - blood; Myocardial Ischemia - diagnostic imaging; Myocardial Ischemia - drug therapy; Myocardial Ischemia - physiopathology; Original Research; saudi arabia; Time Factors; Treatment Outcome; Ventricular Function, Left - drug effects; Ventricular Remodeling - drug effects
• ISSN: 1178-2048; 1176-6344; 1178-2048
• DOI: 10.2147/VHRM.S226009

Left ventricular hypertrophy (LVH), as assessed by measurement of left ventricular mass (LVM), is one of the most important cardiovascular risk factors. It is commonly present in patients with ischemic heart disease (IHD), irrespective of the level of blood pressure; recently, oxidative stress has been shown to be an important factor in its development. The question then arises: can this risk factor be modified by antioxidant treatment (e.g., with allopurinol, a xanthine oxidase inhibitor)? This is an observational study with a cross-sectional design which explored the association between long-term (>12 months) allopurinol therapy and LV mass index (LVMI) as well as geometry in patients generally receiving standard treatments for IHD. The primary endpoint was LVMI measurement (by 2D-echocardiography) and secondary endpoints included the association of allopurinol use with LV function (ejection fraction), blood pressure, glycemic control, and lipid profile. Ninety-six patients on standard anti-ischemic drug treatment (control group) and 96 patients who were additionally taking allopurinol (minimum dose 100 mg/day) were enrolled. Both groups were matched for age, sex, height, and co-morbidities, but poorer kidney function in the allopurinol group required further sub-group analysis based on renal function. Allopurinol treatment was associated with the lowest LVMI in the patients with normal serum creatinine (median LVMI; 70.5 g/m ): corresponding values were 76.0 and 87.0 in the control group with, respectively, normal and elevated serum creatinine, and 89.5 in the allopurinol group with elevated serum creatinine (P=0.027). In addition, allopurinol was associated with better glycemic control (HbA1c) with a difference of 0.8% (95% CI; 1.3, 0.2) (P=0.004) as compared with control patients. In our population, treatment with allopurinol (presumably because of its anti-oxidant properties) has shown a tendency to be associated with smaller LVM in IHD patients with normal serum creatinine, along with better glycemic control.